Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers

References

• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609–1618.
   PubMed Web of Science ®Google Scholar
• DeSantis C, Ma J, Bryan L, et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Forbes JF, Bradley R, et al., Early Breast Cancer Trialists’ Collaborative, G., et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352.
   PubMed Web of Science ®Google Scholar
• Bulun SE, Takayama K, Suzuki T, et al. Organization of the human aromatase p450 (CYP19) gene. Semin Reprod Med. 2004;22(1):5–9.
   PubMed Web of Science ®Google Scholar
• Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(3 Suppl):S116–124.
   PubMed Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003;86(3–5):225–230.
   PubMed Web of Science ®Google Scholar
• Czajka-Oraniec I, Simpson ER. Aromatase research and its clinical significance. Endokrynol Pol. 2010;61(1):126–134.
   PubMed Web of Science ®Google Scholar
• Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004;9(2):126–136.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081–1092.
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS, et al., Breast International Group 1-98 Collaborative, G., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757.
   PubMed Web of Science ®Google Scholar
• Arimidex TAOICTG, Forbes JF, Cuzick J, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.
   PubMed Web of Science ®Google Scholar
• Chumsri S, Howes T, Bao T, et al. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011;125(1–2):13–22.
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20(3):751–757.
   PubMed Web of Science ®Google Scholar
• Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract. 2007;61(12):2051–2063.
   PubMed Web of Science ®Google Scholar
• Qu X, Zhang X, Qin A, et al. Bone mineral density and risk of breast cancer in postmenopausal women. Breast Cancer Res Treat. 2013;138(1):261–271.
   PubMed Web of Science ®Google Scholar
• Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877–3883.
   PubMed Web of Science ®Google Scholar
• Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365–372.
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005;23(28):6931–6940.
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol. 2004;22(21):4261–4271.
   PubMed Web of Science ®Google Scholar
• Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24(6):910–917.
   PubMed Web of Science ®Google Scholar
• Swenson KK, Nissen MJ, Henly SJ, et al. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors. Oncol Nurs Forum. 2013;40(6):549–557.
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–62.
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–2391.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu K, Song Y, et al. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer. PLoS One. 2013;8(7):e68798.
   PubMed Web of Science ®Google Scholar
• Henry NL, Skaar TC, Dantzer J, et al. Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer. Breast Cancer Res Treat. 2013;138(3):807–816.
   PubMed Web of Science ®Google Scholar
• Garcia-Giralt N, Rodríguez-Sanz M, Prieto-Alhambra D, et al. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat. 2013;140(2):385–395.
   PubMed Web of Science ®Google Scholar
• Mao JJ, Su HI, Feng R, et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res. 2011 Jan 20;13(1).
   PubMed Web of Science ®Google Scholar
• Park IH, Lee Y-S, Lee KS, et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2011;68(5):1263–1271.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu K, Song Y, et al. RANKL and OPG polymorphisms are associated with aromatase inhibitor-related musculoskeletal adverse events in Chinese han breast cancer patients. PLoS One. 2015;10(7):e0133964.
   PubMed Web of Science ®Google Scholar
• Lintermans A, Van Asten K, Jongen L, et al. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients. Eur J Cancer. 2016;56:31–36.
   PubMed Web of Science ®Google Scholar
• Ingle JN, Schaid DJ, Goss PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol. 2010;28(31):4674–4682.
   PubMed Web of Science ®Google Scholar
• Liu M, Wang L, Bongartz T, et al. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res. 2012 Mar 9;14(2):R41.
   PubMed Web of Science ®Google Scholar
• Desta Z, Kreutz Y, Nguyen AT, et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther. 2011;90(5):693–700.
   PubMed Web of Science ®Google Scholar
• Wang D, Sadee W. CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing. Pharmacogenet Genomics. 2016;26(1):40–43.
   PubMed Web of Science ®Google Scholar
• Lamba J, Hebert JM, Schuetz EG, et al. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics. 2012;22(7):555–558.
   PubMed Web of Science ®Google Scholar
• Sun D, Chen G, Dellinger RW, et al. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics. 2010;20(10):575–585.
   PubMed Web of Science ®Google Scholar
• Cecil RL, R., C. and A. B. Arthritis of the menopause. JAMA. 1925;84:75–79.
   Google Scholar
• Ho SC, Chan SG, Yip YB, et al. Menopausal symptoms and symptom clustering in Chinese women. Maturitas. 1999;33(3):219–227.
   PubMed Web of Science ®Google Scholar
• Cirillo DJ, Wallace RB, Wu L, et al. Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative. Arthritis Rheum. 2006;54(10):3194–3204.
   PubMed Web of Science ®Google Scholar
• Ma CX, Adjei AA, Salavaggione OE, et al. Human aromatase: gene resequencing and functional genomics. Cancer Res. 2005;65(23):11071–11082.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gustafsson J-Å. Estrogen receptor mutations and functional consequences for breast cancer. Trends Endocrinol Metab. 2015;26(9):467–476.
   PubMed Web of Science ®Google Scholar
• Islander U, Jochems C, Lagerquist MK, et al. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol. 2011;335(1):14–29.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Villaggio B, Seriolo B, et al. Synovial fluid estrogens in rheumatoid arthritis. Autoimmun Rev. 2004;3(3):193–198.
   PubMed Web of Science ®Google Scholar
• Henry NL, Pchejetski D, A’Hern R, et al. Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer. 2010;103(3):291–296.
   PubMed Web of Science ®Google Scholar
• Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008;26(19):3147–3152.
   PubMed Web of Science ®Google Scholar
• Krakauer T. Nuclear factor-kappaB: fine-tuning a central integrator of diverse biologic stimuli. Int Rev Immunol. 2008;27(5):286–292.
   PubMed Web of Science ®Google Scholar
• Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev. 2010;42(1):182–194.
   PubMed Web of Science ®Google Scholar
• Jeong S, Woo MM, Flockhart DA, et al. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4’-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009;64(5):867–875.
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos. 2011;39(1):98–105.
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Liu Y, Stearns V, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010;70(6):854–869.
   PubMed Web of Science ®Google Scholar
• Allen KD, DeVellis RF, Renner JB, et al. Validity and factor structure of the AUSCAN Osteoarthritis Hand Index in a community-based sample. Osteoarthritis Cartilage/ Osteoarthritis Res Soc. 2007;15(7):830–836.
   PubMed Web of Science ®Google Scholar
• Briot K, Tubiana-Hulin M, Bastit L, et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127–134.
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Hoffmann EB, Rao Y, et al. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 2004;14(9):615–626.
   PubMedGoogle Scholar
• Wiener D, Fang J-L, Dossett N, et al. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res. 2004;64(3):1190–1196.
   PubMed Web of Science ®Google Scholar
• Ingle JN, Buzdar AU, Schaid DJ, et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res. 2010;70(8):3278–3286.
   PubMed Web of Science ®Google Scholar
• Chen SM, Atchley DH, Murphy MA, et al. Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-hydroexemestane in Healthy Volunteers. J Clin Pharmacol. 2015;56(7):875–884.
   PubMed Web of Science ®Google Scholar
• Singer O, Cigler T, Moore AB, et al. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms. Breast J. 2014;20(2):174–179.
   PubMed Web of Science ®Google Scholar
• Servitja S, Martos T, Rodriguez Sanz M, et al. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. Ther Adv Med Oncol. 2015;7(5):291–296.
   PubMed Web of Science ®Google Scholar
• Rastelli AL, Taylor ME, Gao F, et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat. 2011;129(1):107–116.
   PubMed Web of Science ®Google Scholar
• Ding C, Gao D, Wilding J, et al. Vitamin D signalling in adipose tissue. Br J Nutr. 2012;108(11):1915–1923.
   PubMed Web of Science ®Google Scholar
• Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443–1449.
   PubMed Web of Science ®Google Scholar
• Van Hoof HJ, Van Der Mooren MJ, Swinkels LM, et al. Female sex hormone replacement therapy increases serum free 1,25-dihydroxyvitamin D3: a 1-year prospective study. Clin Endocrinol (Oxf). 1999;50(4):511–516.
   PubMed Web of Science ®Google Scholar
• Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S–6S.
   PubMed Web of Science ®Google Scholar
• Arai H, Miyamoto KI, Yoshida M, et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res. 2001;16(7):1256–1264.
   PubMed Web of Science ®Google Scholar
• Dai ZM, Fei YL, Zhang WG, et al. Association of Vitamin D Receptor Cdx-2 Polymorphism With Cancer Risk: A Meta-Analysis. Medicine 2015 Aug;94(33):e1370.
   Google Scholar